Biotech News

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Foghorn Therapeutics (FHTX)Foghorn Therapeutics2026-01-10 03:20 ESTFinancing

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)

Related news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-05 11:00 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-05-12 11:00 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-05-07 11:00 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-04-21 20:05 EST

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Stock data

Close: 7.07 USD
Market cap: 213.13M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States